Patents by Inventor Jonnie R. Williams

Jonnie R. Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11938126
    Abstract: In some aspects, isomyosmine or a pharmaceutically acceptable salt thereof may be administered to an individual for the treatment of diseases of the visual system.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: March 26, 2024
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 11807604
    Abstract: Pharmaceutical compounds are disclosed which may be useful for treating asthma, ongoing lung disease, chronic obstructive pulmonary disease (COPD), chronic bronchitis, and/or emphysema. A pharmaceutical composition may include a therapeutically effective amount of the compound and a pharmaceutically acceptable vehicle therefor. The pharmaceutical composition may be administered for treating such disorders as asthma, ongoing lung disease, chronic obstructive pulmonary disease (COPD), chronic bronchitis, or emphysema.
    Type: Grant
    Filed: February 15, 2023
    Date of Patent: November 7, 2023
    Assignee: Miralogx LLC
    Inventor: Jonnie R. Williams, Sr.
  • Patent number: 11767329
    Abstract: Antibacterial compounds are shown and described. In one aspect, a pharmaceutical composition includes a therapeutically effective amount of an antibacterial compound and a pharmaceutically acceptable vehicle therefor. In another aspect, a method of treating a bacterial infection involves administering the pharmaceutical composition to an individual in need thereof.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: September 26, 2023
    Assignee: Miralogx LLC
    Inventor: Jonnie R. Williams, Sr.
  • Publication number: 20230295125
    Abstract: Pharmaceutical compounds have anti-inflammatory activity and, in some aspects, may function as metalloenzyme inhibitors for the beneficial regulation of metalloproteins. A pharmaceutical composition may include a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle. The pharmaceutical compositions may be useful for treating a disorder associated with chronic inflammation and/or metalloenzyme misregulation, including hemochromatosis, cancers such as breast cancer, or neurodegenerative diseases such as Alzheimer’s disease.
    Type: Application
    Filed: April 14, 2023
    Publication date: September 21, 2023
    Applicant: Miralogx LLC
    Inventor: Jonnie R. Williams, SR.
  • Publication number: 20230212597
    Abstract: Synthetic cannabinoid compounds for treatment of pain and anxiety by administering to an individual in need thereof a pharmaceutical composition including a compound having the structure: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.
    Type: Application
    Filed: February 20, 2023
    Publication date: July 6, 2023
    Inventor: Jonnie R. Williams
  • Patent number: 11629355
    Abstract: Synthetic cannabinoid compounds for treatment of epilepsy, substance addiction, and Alzheimer's disease by administering to an individual in need thereof a pharmaceutical composition including a compound having the structure: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: April 18, 2023
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Publication number: 20220339147
    Abstract: In some aspects, isomyosmine or a pharmaceutically acceptable salt thereof may be administered to an individual for the treatment of diseases of the visual system.
    Type: Application
    Filed: June 28, 2022
    Publication date: October 27, 2022
    Inventor: Jonnie R. Williams
  • Patent number: 11331310
    Abstract: A pharmaceutical composition containing isomyosmine or a pharmaceutically acceptable salt thereof is administered to an individual in need thereof for treating a substance addiction, inclusive of addiction to heroin (diacetylmorphine), cocaine, opioids, methadone, d-methamphetamine, barbiturates, alcohol, benzodiazepines, amphetamines, or buprenorphine. The isomyosmine, along with optional additional therapeutic agent(s), may be administered in a capsule, tablet, or lozenge.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: May 17, 2022
    Assignee: MyMD Pharmaceuticals (Florida), Inc.
    Inventor: Jonnie R. Williams
  • Publication number: 20220062261
    Abstract: In some aspects, a method of regulating oxidoreductase activity for treating an inflammation or age-related disorder involves administering to an individual isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, a method of treating oxidative stress associated with an inflammation or age-related disorder involves administering to an individual a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, isomyosmine or a pharmaceutically acceptable salt thereof may be administered to an individual for the treatment of infectious or parasitic diseases or various other disorders.
    Type: Application
    Filed: November 11, 2021
    Publication date: March 3, 2022
    Inventor: Jonnie R. Williams
  • Patent number: 11219620
    Abstract: In some aspects, a method of regulating oxidoreductase activity for treating an inflammation or age-related disorder involves administering to an individual isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, a method of treating oxidative stress associated with an inflammation or age-related disorder involves administering to an individual a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, isomyosmine or a pharmaceutically acceptable salt thereof may be administered to an individual for the treatment of infectious or parasitic diseases or various other disorders.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: January 11, 2022
    Assignee: MyMD Pharmaceuticals (Florida), Inc.
    Inventor: Jonnie R. Williams
  • Publication number: 20210380998
    Abstract: A method of increasing the cannabinoid levels in a genetically modified Cannabis sativa plant includes genetically modifying the plant to induce the overexpression of the gene that controls the expression of tetrahydrocannabinolic acid (THCA) synthase and/or cannabidiolic acid (CBDA) synthase. The overexpression of THCA synthase and CBDA synthase catalyzes an increased synthesis of cannabigerolic acid to tetrahydrocannabinolic acid and cannabidiolic acid, as well as the cannabinoids (3aR)-2,4,4-trimethyl-7-pentyl-3,3a,4,9b-tetrahydrocyclopenta[c]chromen-9-ol and 2-((1R,5R)-3-methyl-5-(prop-1-en-2-yl)cyclopent-2-en-1-yl)-5-pentylbenzene-1,3-diol. Pharmaceutical compositions comprising the modified cannabinoids produced by the transgenic Cannabis sativa plant or prepared synthetically are used to treat various diseases and conditions.
    Type: Application
    Filed: July 22, 2021
    Publication date: December 9, 2021
    Inventor: Jonnie R. Williams
  • Patent number: 11191736
    Abstract: In one aspect, a method of treating smokeless tobacco addiction comprising administering to an individual in need thereof a pharmaceutical composition comprising nicotine, a therapeutically effective amount of cannabidiol, and a pharmaceutically acceptable vehicle therefor. In some aspects, the composition is administered transmucosally, such as in an oral dosage form or nasal spray. In other aspects, the composition is administered transdermally. In another aspect, a chewable gum contains nicotine in at least a base portion and cannabidiol in at least an outer portion thereof.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: December 7, 2021
    Assignee: CV Sciences, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 11179382
    Abstract: In one aspect, a method of altering programmed cell death includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, isomyosmine is administered to treat a wound, hemochromatosis, traumatic brain injury, or disorders associated with chronic oxidative stress. In other aspects, isomyosmine is administered to increase blood oxygen saturation levels.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: November 23, 2021
    Assignee: MyMD Pharmaceuticals (Florida), Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 11096933
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: August 24, 2021
    Assignee: MyMD Pharmaceuticals (Florida), Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 11085047
    Abstract: A method of increasing the cannabinoid levels in a genetically modified Cannabis sativa plant includes genetically modifying the plant to induce the overexpression of the gene that controls the expression of tetrahydrocannabinolic acid (THCA) synthase and/or cannabidiolic acid (CBDA) synthase. The overexpression of THCA synthase and CBDA synthase catalyzes an increased synthesis of cannabigerolic acid to tetrahydrocannabinolic acid and cannabidiolic acid, as well as the cannabinoids (3aR)-2,4,4-trimethyl-7-pentyl-3,3a,4,9b-tetrahydrocyclopenta[c]chromen-9-ol and 2-((1R,5R)-3-methyl-5-(prop-1-en-2-yl)cyclopent-2-en-1-yl)-5-pentylbenzene-1,3-diol. Pharmaceutical compositions comprising the modified cannabinoids produced by the transgenic Cannabis sativa plant or prepared synthetically are used to treat various diseases and conditions.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: August 10, 2021
    Assignee: MyMD Pharmaceuticals (Florida), Inc.
    Inventor: Jonnie R. Williams
  • Publication number: 20210106578
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Application
    Filed: October 29, 2020
    Publication date: April 15, 2021
    Inventor: Jonnie R. Williams
  • Patent number: 10918633
    Abstract: In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: February 16, 2021
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10835523
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: November 17, 2020
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Publication number: 20200338061
    Abstract: In some aspects, a method of regulating oxidoreductase activity for treating an inflammation or age-related disorder involves administering to an individual isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, a method of treating oxidative stress associated with an inflammation or age-related disorder involves administering to an individual a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, isomyosmine or a pharmaceutically acceptable salt thereof may be administered to an individual for the treatment of infectious or parasitic diseases or various other disorders.
    Type: Application
    Filed: July 14, 2020
    Publication date: October 29, 2020
    Inventor: Jonnie R. Williams
  • Patent number: 10806728
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: October 20, 2020
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams